TY - JOUR
T1 - Rationale and design of a trial on the effect of angiotensin II receptor blockers on the function of the systemic right ventricle
AU - van der Bom, Teun
AU - Winter, Michiel M.
AU - Bouma, Berto J.
AU - Groenink, Maarten
AU - Vliegen, Hubert W.
AU - Pieper, Petronella G.
AU - van Dijk, Arie P. J.
AU - Sieswerda, Gertjan T.
AU - Roos-Hesslink, Jolien W.
AU - Zwinderman, Aielko H.
AU - Mulder, Barbara J. M.
PY - 2010
Y1 - 2010
N2 - Background Angiotensin II receptor blockers have been proven to be beneficial in left ventricular failure. In patients with a morphologic right ventricle supporting the systemic circulation, its efficacy has not yet been established. Methods We designed a multicenter, prospective, randomized, double-blind, placebo-controlled trial studying the effect of valsartan in patients with a systemic right ventricle due to a congenitally or surgically corrected transposition of the great arteries. The primary end point is the change in right ventricular ejection fraction as measured by cardiovascular magnetic resonance or multidetector row cardiac computed tomography in case of pacemaker patients. Conclusion This large prospective, double-blind, randomized, placebo-controlled trial will establish the role of angiotensin II receptor blockers (valsartan) in the treatment of patients with a systemic right ventricle. (Am Heart J 2010;160:812-8.)
AB - Background Angiotensin II receptor blockers have been proven to be beneficial in left ventricular failure. In patients with a morphologic right ventricle supporting the systemic circulation, its efficacy has not yet been established. Methods We designed a multicenter, prospective, randomized, double-blind, placebo-controlled trial studying the effect of valsartan in patients with a systemic right ventricle due to a congenitally or surgically corrected transposition of the great arteries. The primary end point is the change in right ventricular ejection fraction as measured by cardiovascular magnetic resonance or multidetector row cardiac computed tomography in case of pacemaker patients. Conclusion This large prospective, double-blind, randomized, placebo-controlled trial will establish the role of angiotensin II receptor blockers (valsartan) in the treatment of patients with a systemic right ventricle. (Am Heart J 2010;160:812-8.)
U2 - https://doi.org/10.1016/j.ahj.2010.08.005
DO - https://doi.org/10.1016/j.ahj.2010.08.005
M3 - Article
C2 - 21095266
SN - 0002-8703
VL - 160
SP - 812
EP - 818
JO - American Heart Journal
JF - American Heart Journal
IS - 5
ER -